Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

G Kris, Mark; B Natale, Ronald; S Herbst, Roy; J Lynch, Thomas; Prager, Diane; P Belani, Chandra; H Schiller, Joan; Kelly, Karen; Spiridonidis, Harris; Sandler, Alan; S Albain, Kathy; Cella, David; K Wolf, Michael; D Averbuch, Steven; J Ochs, Judith; C Kay, Andrea

doi:10.1001/jama.290.16.2149

Public

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Published in JAMA • Oct 22, 2003

NobleIDark:/48914/w1/20260526/11386CB3Record on NobleID

Authors:

Mark G Kris

,

Ronald B Natale

,

Roy S Herbst

Abstract

CONTEXT: More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell ...

Discussions